QuidelOrtho To Report First Quarter 2024 Financial Results

Rhea-AI Summary

QuidelOrtho (Nasdaq: QDEL) will report its financial results for the first quarter of 2024 on May 8, 2024. The company specializes in in vitro diagnostic technologies for various medical settings. A conference call will follow the release of financial results for interested parties to discuss the performance.

SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.

Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 295379.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website under the “Events & Presentations” section.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit www.quidelortho.com.

Source: QuidelOrtho Corporation

View source version on businesswire.com: https://www.businesswire.com/news/home/20240417178380/en/

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

IR@QuidelOrtho.com

Media Contact:

D. Nikki Wheeler

Senior Director, Corporate Communications

media@QuidelOrtho.com

Source: QuidelOrtho Corporation

FAQ

When will QuidelOrtho report its financial results for the first quarter of 2024?

QuidelOrtho will report its financial results for the first quarter of 2024 on May 8, 2024.

What does QuidelOrtho specialize in?

QuidelOrtho specializes in in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine.

How can interested parties access the conference call to discuss QuidelOrtho's financial results?

Interested parties can access the conference call on the 'Events & Presentations' section of the 'Investor Relations' page of QuidelOrtho's website at the specified time.

What are the dial-in details for joining the conference call if unable to access the webcast?

Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 295379.

Will there be a replay of the conference call available?

Yes, a replay of the conference call will be available shortly after the event on the 'Investor Relations' page of QuidelOrtho's website.